Accu Reference Medical Lab Offers New Prostate Cancer Test, Reduces Unnecessary Biopsies

Linden, New Jersey ? Accu Reference Medical Lab, in collaboration?with Beckman Coulter, is now?offering?amongst its general health testing services a new prostate cancer-screening assay known as the prostate health index (or phi) test.

Currently, prostate biomarkers are used to detect prostate cancer in men 50 and over. The foremost diagnostic tool regardless of its severe restrictions, Prostate-specific antigen (PSA) is still considered the gold standard at present. However, research studies for new and accurate new diagnostic tools are still ongoing. Furthermore, a majority of the studies conducted in clinical lab?regards to PSA are subjected to assignment bias, that tends to cause limitations in the accuracy of the results. ?Since a PSA cut-off value of 4.0 ng/ml, which is a frequently used biopsy indicator, missed about 75% of all biopsy-detectable cancers. On the other spectrum, a detection rate of 21.9% was found in sextant biopsies in all male patients. ?One way out of this dilemma is to come out with a better test and offer the patients more options. As cases that present with low PSA ranges could not be doubtful?with the current use of available risk indicator nomograms.?
The phi test may assist doctors in differentiating?the ever so notorious prostate cancer from benign prostate conditions. Moreover, the results of this test are research-driven, which was created?by Beckman Coulter, and according to them, the phi decreases uncalled for?biopsies by about 30 percent. It is also a FDA-approved test. This test is readily offered to health care providers (HCPs) via Accu Reference Medical Lab (ARML). ARML in conjunction with Beckman Coulter is able to offer this?test to its consumers. Moreover, the phi score aids in making a decision whether or not to obtain a biopsy in the prostate of male patients whose total PSA drops?within a diagnostic grey area.??
Study reference: Catalona WI, Partin AW, Sanda MG, et al: A multicenter study of pro-prostate specific antigen combined with prostate specific antigen and the free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011 May; 185(5):1650-1655.


About ACCU Reference Medical Lab
ACCU Reference Medical Lab is a New Jersey-based full-service medical testing laboratory. Established in 2005, ACCU Reference Medical Lab serves healthcare providers in 19 states and employs over 750 highly educated and well-trained professionals. In addition to its commitment to a robust compliance plan, the laboratory has emerged as the regional leader in the fields of toxicology,?pharmacogenetics?and molecular testing, in addition to routine blood and urine testing. In particular, ACCU Reference Medical Lab has revolutionized testing for respiratory and gastrointestinal diseases, which allows for a significantly earlier detection of pathogens than any other technology.
About Beckman Coulter
Beckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need when they need it. For more than 80 years, Beckman Coulter has been the partner of choice for healthcare organizations. Our scalable instruments, comprehensive diagnostic tests, and business management services are trusted by hospitals, laboratories, and other critical care settings around the world. We share in our customers? mission toward continuous improvement and quality patient care because we believe when efficiency and clinical outcomes are improved, patients benefit, and we can move health care forward for every person.

Company :-Accu Reference Medical Lab

User :- Accu Reference Medical Lab

Email :-brown.cheere@gmail.com

Phone :-877-733-4522

Mobile:- -

Url :- https://www.accureference.com